Brought to you by 
GSK to develop Amira's FLAP blockers for asthma, CV diseases
26 Jul 2011
Executive Summary
Amira Pharmaceuticals (start-up focusing on eicosanoid pathway-related inflammation) has licensed GlaxoSmithKline exclusive global rights to develop, manufacture, and sell its FLAP (5-lipoxygenase-activating protein) inhibitors for respiratory and cardiovascular diseases.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GSK to develop Amira's FLAP blockers for asthma, CV diseases
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice